<DOC>
	<DOCNO>NCT01777737</DOCNO>
	<brief_summary>First study test validity treatment idiopathic pulmonary fibrosis , cause inflammation fibrosis ( scar ) lung tissue , cotrimoxazole . Cotrimoxazole may improve clinical course disease eradication Pneumocystis jiroveci colonization mechanism inhibit activation alveolar macrophage produce alteration surfactant system favours persistent activation inflammatory response development pulmonary fibrosis .</brief_summary>
	<brief_title>Study Test Validity Treatment Idiopathic Pulmonary Fibrosis With Cotrimoxazole</brief_title>
	<detailed_description>Idiopathic pulmonary fibrosis ( IPF ) chronic lung disease clinically manifest appearance effort dyspnea impair lung function . The natural history disease poorly understood clear consensus appropriate marker predict patient outcome . This pilot control trial aim test efficacy safety cotrimoxazole treatment IPF . This novel therapeutic strategy , encourage preliminary data base pathophysiological basis , primarily relate elimination Pneumocystis colonization . That elimination , could serve potent weapon reduce morbidity mortality cost associate devastate disease .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<criteria>Patient , regardless gender , age 18 80 year . Wellestablished diagnostic criterion Idiopathic Pulmonary Fibrosis ( IPF ) ATA/ERS/JRS/ALAT 2011 . Ability obtain sample sputum oropharyngeal wash . Forced Vital Capacity ( FVC ) 50 % theoretical value expect . Patient compliance legal guardian participate study signing inform consent . Allergy / hypersensitivity know gastrointestinal intolerance cotrimoxazole . Use immunosuppressant corticosteroids previous 90 day baseline . Exacerbation IPF / pneumonia 90 day prior baseline . Presence autoimmune disease asthma . Patients significant disease IPF . It consider significant disease disease condition , investigator 's opinion , may jeopardize patient 's health participating study influence result study patient 's ability participate study . Pregnant lactate childbearing potential use medically approve contraceptive method least three month trial . Participation another trial investigational drug within 30 day six halflives ( large two ) baseline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Idiopathic Pulmonary Fibrosis</keyword>
	<keyword>Trimethoprim-sulfamethoxazole</keyword>
	<keyword>Pneumocystis jiroveci</keyword>
</DOC>